Loading organizations...
Endogena Therapeutics is a clinical-stage biopharmaceutical company based in Schlieren, Switzerland, that develops endogenous regenerative medicines to repair diseased tissues and organs. The enterprise combines artificial intelligence, stem cell biology, and small-molecule drug design to activate the body's innate regenerative abilities for treating degenerative eye conditions and aging-related diseases. Operating with a team of 21 employees, the biotechnology firm generates an estimated $1.6 million in annual revenue while advancing its proprietary therapeutic pipeline. Endogena has raised $29 million in total funding, including a $20 million Series A round backed by institutional investors such as Rejuveron Life Sciences AG and Centenara Labs AG. The organization recently achieved clinical proof-of-concept for its primary asset, dicholine succinate, to address severe retinal degeneration. The company was founded in 2016 by Matthias Steger and Gisbert Schneider, a professor at ETH Zürich.
Endogena has raised $29.0M across 2 funding rounds.
Key people at Endogena.
Endogena has raised $29.0M in total across 2 funding rounds.
Endogena has raised $29.0M across 2 funding rounds. Most recently, it raised $21.0M Series A in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 1, 2021 | $21M Series A | — | DEFTA Partners, Founders Fund, Presight Capital | Announced |
| Jan 1, 2021 | $8M Series A | — | DEFTA Partners, Founders Fund, Presight Capital | Announced |
Key people at Endogena.
# Endogena Therapeutics: A Regenerative Medicine Pioneer
Endogena is not a technology company in the traditional sense—it is a clinical-stage biotechnology firm specializing in regenerative medicines.[1][2] The company discovers and develops first-in-class endogenous regenerative treatments designed to repair and regenerate damaged tissues and organs by selectively regulating endogenous adult stem and progenitor cells through small-molecule drugs.[2]
Endogena targets degenerative diseases associated with aging and genetic disorders, with its most advanced programs focused on eye diseases including retinitis pigmentosa (RP) and geographic atrophy (a form of age-related macular degeneration).[2] The company combines stem cell biology, artificial intelligence, and small-molecule drug design to create a novel treatment paradigm that differs fundamentally from conventional approaches.[1][2]
The company operates as a clinical-stage biotech with operations based in Zürich's Bio-Technopark and at JLABS in Toronto, Canada, and is part of the Rejuveron Life Sciences group of companies.[2] Rather than building software or digital platforms, Endogena is developing pharmaceutical products that address unmet medical needs in regenerative medicine—a field with significant potential to transform treatment of age-related and genetic conditions.
Endogena operates at the intersection of regenerative medicine and aging biology—two of the most dynamic areas in biotechnology. The company's focus on endogenous stem cell activation through small molecules addresses a critical gap: most current treatments for degenerative diseases are palliative rather than regenerative. As populations age globally, demand for therapies that can actually repair damaged tissues rather than merely slow decline is accelerating.
The timing is particularly favorable given advances in stem cell biology, computational drug discovery, and regulatory pathways for regenerative medicines. Endogena's approach could influence how the biotech industry thinks about treating age-related conditions, potentially shifting focus from symptom management to tissue restoration.
Endogena stands at a pivotal moment. With clinical data already being presented at major conferences and regulatory momentum (Fast Track designation), the company's next critical milestones will be Phase 1/2a trial results for EA-2353 and progression of its AMD program toward clinical studies.[5] Success in these programs could validate the broader endogenous regenerative medicine approach and open doors to applications beyond ophthalmology.
The company's future hinges on demonstrating that small-molecule activation of endogenous stem cells can deliver meaningful clinical benefit in patients—a proof-of-concept that could reshape regenerative medicine development across the industry.
Endogena has raised $29.0M in total across 2 funding rounds.
Endogena's investors include DEFTA Partners, Founders Fund, Presight Capital.
